Analysts have been eager to weigh in on the Healthcare sector with new ratings on Tenon Medical, Inc. (TNON – Research Report), Akoya Biosciences (AKYA – Research Report) and Bioxcel Therapeutics (BTAI – Research Report).
Tenon Medical, Inc. (TNON)
In a report released yesterday, Anthony Vendetti from Maxim Group reiterated a Buy rating on Tenon Medical, Inc., with a price target of $6.00. The company’s shares closed last Wednesday at $2.75, close to its 52-week low of $0.77.
According to TipRanks.com, Vendetti ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Tenon Medical, Inc. with a $6.00 average price target, representing a 94.2% upside. In a report released yesterday, Benchmark Co. also maintained a Buy rating on the stock with a $6.00 price target.
See today’s best-performing stocks on TipRanks >>
Akoya Biosciences (AKYA)
Piper Sandler analyst David Westenberg assigned a Buy rating to Akoya Biosciences on November 13 and set a price target of $8.00. The company’s shares closed last Wednesday at $4.45, close to its 52-week low of $3.04.
According to TipRanks.com, Westenberg is a 1-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Akoya Biosciences with a $9.67 average price target, which is an 117.3% upside from current levels. In a report issued on November 9, Canaccord Genuity also maintained a Buy rating on the stock with a $14.00 price target.
Bioxcel Therapeutics (BTAI)
In a report issued on November 14, Graig Suvannavejh from Mizuho Securities maintained a Hold rating on Bioxcel Therapeutics, with a price target of $4.00. The company’s shares closed last Wednesday at $4.40, close to its 52-week low of $2.23.
According to TipRanks.com, Suvannavejh has 0 stars on 0-5 stars ranking scale with an average return of
Bioxcel Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $10.50, implying a 147.1% upside from current levels. In a report issued on November 8, Goldman Sachs also reiterated a Hold rating on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on TNON:
